Gilead Sciences, Inc. (GILD) Analyst Ratings & Price Targets

Gilead Sciences, Inc.

GILD · Nasdaq

Analyst Consensus

Buy

24 analysts

0 Bearish1 Neutral2 Bullish

$146

Current

$165

Low

$165

Average

$165

High

Average target implies +12.70% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 24 analysts. Targets are unusually tightly clustered: the low, mean, and high are all $165, leaving no stated spread and placing the consensus above the $146.64 closing price. Because every reported target is identical, the evidence does not identify a distinctly most bullish or least bullish analyst. No rating or target revisions are explicitly reported during the week beginning September 7. The latest attributable changes in the supplied material predate the week: Morgan Stanley lowered its target from $166 to $165 while retaining Overweight on July 27, and Leerink Partners downgraded Gilead from Outperform to Market Perform on July 21. The substantive disagreement is therefore not visible in the stated current consensus; the data instead show uniform optimism alongside isolated earlier caution.

Rating Actions

3 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Morgan Stanley	—	Overweight Lowered price target	$165from $166	+12.7%	Jul 27, 2026	Open the report this row came from
Leerink Partners	—	Market Perform Downgraded	—	—	Jul 21, 2026	Open the report this row came from
HSBC Holdings plc	—	Buy upgraded	$155from $133	+5.9%	Jul 6, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BMO CAPITAL MKT

CANTOR FITZGERA

CO FORECST

DBS BANK

DEUTSCHE BK SEC

EDWARD JONES

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MAXIM GROUP,LLC

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

TD COWEN

TRUIST SECURITI

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: GILD
Type: Stock
Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Exchange: Nasdaq

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness - while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Key Issues

Bullish view

Gilead secured its third FDA approval in less than four months, while its established HIV franchise remains dominant. Supporters can argue that the approval cadence broadens the product base and improves the turnaround case.

Bearish view

The supplied evidence does not show that the new approvals have yet changed revenue or earnings. The stock’s sharp September 8 decline after reaching $151.22 suggests investors remain unconvinced about near-term commercial impact.

Analyst Consensus

See all

Buy

24 analysts

0 Bearish1 Neutral2 Bullish

$146

Current

$165

Low

$165

Average

$165

High

Average target implies +12.70% versus the current price.

Earnings History

BeatMissNo estimate

Gilead Sciences, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers